C57BL/6N-Txniptm1a(EUCOMM)Hmgu/H

Status

Available to order

EMMA IDEM:07875
International strain nameC57BL/6N-Txniptm1a(EUCOMM)Hmgu/H
Alternative nameHEPD0732_5_F08
Strain typeTargeted Mutant Strains
Allele/Transgene symbolTxniptm1a(EUCOMM)Hmgu
Gene/Transgene symbolTxnip
DisclaimerPlease note that for EUCOMM and KOMP-CSD mice supplied to the scientific community by INFRAFRONTIER/EMMA:
  1. We can not guarantee a null mutation for Knock-out first alleles (tm1a alleles, see http://www.mousephenotype.org/about-ikmc/targeting-strategies) as the critical exon has not been deleted.
  2. That the structure of the targeted mutation in the ES cells obtained from EUCOMM/KOMP to generate EUCOMM/KOMP mice is not verified by INFRAFRONTIER/EMMA. It is recommended that the recipient confirms the mutation structure.
  3. No check for determining the copy number of the targeting construct in ES cells obtained from EUCOMM/KOMP is done by INFRAFRONTIER/EMMA.
  4. The level of quality control before mice are released is to confirm the individual mouse genotype by short range PCR.

Information from provider

Provider MRC, Medical Research Council
Provider affiliationMary Lyon Centre at MRC Harwell
Genetic informationThis mouse line originates from EUCOMM ES clone HEPD0732_5_F08. For further details on the construction of this clone see the page at the IMPC portal.
Phenotypic informationPotential phenotyping data in the IMPC portal
ReferencesNone available

Information from EMMA

Archiving centreMary Lyon Centre at MRC Harwell, Oxford, United Kingdom

Disease and phenotype information

IMPC phenotypes (gene matching)
  • increased circulating triglyceride level / IMPC
  • decreased bone mineral content / IMPC
  • increased circulating calcium level / IMPC
  • abnormal retina morphology / IMPC
  • increased total body fat amount / IMPC
  • decreased bone mineral density / IMPC
  • decreased circulating alkaline phosphatase level / IMPC
  • increased circulating phosphate level / IMPC
MGI phenotypes (gene matching)
  • hypoglycemia / MGI
  • increased circulating triglyceride level / MGI
  • increased circulating free fatty acid level / MGI
  • abnormal circulating insulin level / MGI
  • abnormal glucose homeostasis / MGI
  • abnormal lipid homeostasis / MGI
  • no abnormal phenotype detected / MGI
  • increased circulating ketone body level / MGI
  • abnormal ileum morphology / MGI
  • hepatic steatosis / MGI
  • increased insulin sensitivity / MGI
  • increased liver weight / MGI
  • liver degeneration / MGI
  • increased hepatocellular carcinoma incidence / MGI
  • abnormal gluconeogenesis / MGI
  • kidney failure / MGI
  • abnormal heart left ventricle morphology / MGI
  • impaired cellular glucose import / MGI
  • altered response of heart to induced stress / MGI
  • increased regulatory T cell number / MGI
  • increased lymphocyte cell number / MGI
  • abnormal NK cell morphology / MGI
  • increased circulating VLDL cholesterol level / MGI
  • hematuria / MGI
  • increased circulating cholesterol level / MGI
  • abnormal mesenteric lymph node morphology / MGI
  • increased fatty acid level / MGI
  • improved glucose tolerance / MGI
  • increased T cell proliferation / MGI
  • homeostasis/metabolism phenotype / MGI
  • growth/size/body region phenotype / MGI
  • cardiovascular system phenotype / MGI
  • reproductive system phenotype / MGI
  • decreased circulating glucose level / MGI
  • increased blood urea nitrogen level / MGI
  • decreased ventricle muscle contractility / MGI
  • increased bleeding time / MGI
  • increased circulating potassium level / MGI
  • decreased circulating sodium level / MGI
  • abnormal circulating phospholipid level / MGI
  • decreased NK T cell number / MGI
  • decreased NK cell number / MGI
  • decreased CD8-positive, alpha-beta T cell number / MGI
  • decreased physiological sensitivity to xenobiotic / MGI
  • abnormal blood homeostasis / MGI
  • increased sensitivity to induced morbidity/mortality / MGI
  • abnormal NK cell physiology / MGI
  • mortality/aging / MGI
  • abnormal cellular respiration / MGI
  • decreased circulating antithrombin level / MGI
  • increased prothrombin time / MGI
  • increased partial thromboplastin time / MGI
  • increased circulating lactate level / MGI
  • increased cardiac cell glucose uptake / MGI
  • increased muscle cell glucose uptake / MGI

Information on how we integrate external resources can be found here

Order

Availabilities

Requesting frozen sperm or embryos is generally advisable wherever possible, in order to minimise the shipment of live mice.

Due to the dynamic nature of our processes strain availability may change at short notice. The local repository manager will advise you in these circumstances.

* In addition users have to cover all the shipping costs (including the cost for returning dry-shippers, where applicable).

More details on pricing and delivery times

Practical information

Genotyping protocol

Example health report
(Current health report will be provided later)

Material Transfer Agreement (MTA)
MTA will be issued after an order has been submitted.

EMMA conditions
Legally binding conditions for the transfer

Other EMMA strains

Not found what you were looking for? Search here for other strains available from EMMA.


Search
INFRAFRONTIER® and European Mouse Mutant Archive - EMMA® are registered trademarks at the European Union Intellectual Property Office (EUIPO).